tetano
Editor, Senior Moderator
Eur J Med Chem
. 2021 Jan 12;213:113157.
doi: 10.1016/j.ejmech.2021.113157. Online ahead of print.
The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2
Shagufta[SUP] 1 [/SUP], Irshad Ahmad[SUP] 2 [/SUP]
Affiliations
Abstract
The unforeseen emergence of coronavirus disease 2019 (COVID-19), a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at the Wuhan province of China in December 2019, subsequently its abrupt spread across the world has severely affected human life. In a short span of time, COVID-19 has sacked more than one million human lives and marked as a severe global pandemic, which is drastically accountable for the adverse effect directly to the human society, particularly the health care system and the economy. The unavailability of approved and effective drugs or vaccines against COVID-19 further created conditions more adverse and terrifying. To win the war against this pandemic within time there is a desperate need for the most adequate therapeutic treatment, which can be achieved by the collaborative research work among scientists worldwide. In continuation of our efforts to support the scientific community, a review has been presented which discusses the structure and the activity of numerous molecules exhibiting promising SARS-CoV-2 and other CoVs inhibition activities. Furthermore, this review offers an overview of the structure, a plausible mechanism of action of SARS-CoV-2, and crucial structural features substantial to inhibit the primary virus-based and host-based targets involved in SARS-CoV-2 treatment. We anticipate optimistically that this perspective will provide the reader and researcher's better understanding regarding COVID-19 and pave the path in the direction of COVID-19 drug discovery and development paradigm.
Keywords: 3CL protease; ACE-2 receptor; COVID-19; Cathepsin L proteinase; Coronavirus; Inhibitors. contents; RdRp; SARS-CoV-2; Spike glycoprotein; TMPRSS2.
. 2021 Jan 12;213:113157.
doi: 10.1016/j.ejmech.2021.113157. Online ahead of print.
The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2
Shagufta[SUP] 1 [/SUP], Irshad Ahmad[SUP] 2 [/SUP]
Affiliations
- PMID: 33486200
- DOI: 10.1016/j.ejmech.2021.113157
Abstract
The unforeseen emergence of coronavirus disease 2019 (COVID-19), a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at the Wuhan province of China in December 2019, subsequently its abrupt spread across the world has severely affected human life. In a short span of time, COVID-19 has sacked more than one million human lives and marked as a severe global pandemic, which is drastically accountable for the adverse effect directly to the human society, particularly the health care system and the economy. The unavailability of approved and effective drugs or vaccines against COVID-19 further created conditions more adverse and terrifying. To win the war against this pandemic within time there is a desperate need for the most adequate therapeutic treatment, which can be achieved by the collaborative research work among scientists worldwide. In continuation of our efforts to support the scientific community, a review has been presented which discusses the structure and the activity of numerous molecules exhibiting promising SARS-CoV-2 and other CoVs inhibition activities. Furthermore, this review offers an overview of the structure, a plausible mechanism of action of SARS-CoV-2, and crucial structural features substantial to inhibit the primary virus-based and host-based targets involved in SARS-CoV-2 treatment. We anticipate optimistically that this perspective will provide the reader and researcher's better understanding regarding COVID-19 and pave the path in the direction of COVID-19 drug discovery and development paradigm.
Keywords: 3CL protease; ACE-2 receptor; COVID-19; Cathepsin L proteinase; Coronavirus; Inhibitors. contents; RdRp; SARS-CoV-2; Spike glycoprotein; TMPRSS2.